Intensity Therapeutics, Inc.(INTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INTS Intensity Therapeutics, Inc.

Closed Martin Luther King, Jr. Day 01-16 16:00:00 EST

0.4083

-0.0098

-2.34%

盘后0.4015

-0.0068-1.67%

19:49 EST

High0.4175	Low0.4000	Vol761.11K
Open0.4100	D1 Closing0.4181	Amplitude4.19%
Mkt Cap24.52M	Tradable Cap21.95M	Total Shares60.06M
T/O309.80K	T/O Rate1.42%	Tradable Shares53.76M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INTS","market":"US","secType":"STK","nameCN":"Intensity Therapeutics, Inc.","latestPrice":0.4083,"timestamp":1768597200000,"preClose":0.4181,"halted":0,"volume":761112,"hourTrading":{"tag":"盘后","latestPrice":0.4015,"preClose":0.4083,"latestTime":"19:49 EST","volume":39554,"amount":16187.2526,"timestamp":1768610987903,"change":-0.0068,"changeRate":-0.016654,"amplitude":0},"delay":0,"changeRate":-0.023439368572112006,"floatShares":53763500,"shares":60064965,"eps":-0.511421,"marketStatus":"Closed Martin Luther King, Jr. Day","change":-0.0098,"latestTime":"01-16 16:00:00 EST","open":0.41,"high":0.4175,"low":0.4,"amount":309798.461808,"amplitude":0.041856,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.511421,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"listingDate":1666324800000,"exchange":"NASDAQ","adjPreClose":0.4181,"preHourTrading":{"tag":"盘前","latestPrice":0.4178,"preClose":0.4181,"latestTime":"09:29 EST","volume":4052,"amount":1688.893982,"timestamp":1768573766013,"change":-0.0003,"changeRate":-0.000718,"amplitude":0.04066},"postHourTrading":{"tag":"盘后","latestPrice":0.4015,"preClose":0.4083,"latestTime":"19:49 EST","volume":39554,"amount":16187.2526,"timestamp":1768610987903,"change":-0.0068,"changeRate":-0.016654,"amplitude":0},"volumeRatio":0.7252885480216109},"requestUrl":"/m/hq/s/INTS/tweets","defaultTab":"tweets","newsList":[{"id":"2603681119","title":"BRIEF-Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681119","media":"Reuters","labels":["dataReport","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681119?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:54","pubTimestamp":1768308876,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Highlights 2025 Milestones And Outlines 2026 Strategic PrioritiesJan 13 (Reuters) - Intensity Therapeutics Inc INTS.O:INTENSITY THERAPEUTICS HIGHLIGHTS 2025 MILESTONES AND","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA2RJJTD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2603681340","title":"Intensity Therapeutics Inc. Outlines 2026 Strategy: Pursuing Additional Peer-Reviewed Publications, Advancing Regulatory Engagement, Opportunistically Raising Capital, and Planning Phase 3 Breast Cancer Study Initiation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603681340","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603681340?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:47","pubTimestamp":1768308434,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Inc. Outlines 2026 Strategy: Pursuing Additional Peer-Reviewed Publications, Advancing Regulatory Engagement, Opportunistically Raising Capital, and Planning Phase 3 Breast Cancer Study Initiation. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on January 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL7Yyky4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2603968158","title":"Intensity Therapeutics Inc - Plans to File Protocol Amendment for Invincible-4 Study and Reinitiate Enrollment in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2603968158","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603968158?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:47","pubTimestamp":1768308420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA2RJJTD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2603645681","title":"Intensity Therapeutics Inc: to Raise Additional Capital During 2026 to Reinitiate Patient Enrollment and Site Activations in Invicible-3 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2603645681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603645681?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:47","pubTimestamp":1768308420,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA2RJJTD:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2592964947","title":"Intensity Therapeutics Inc. Releases Clinical Data on Anthracycline-Free Treatment for Early-Stage Triple Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2592964947","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592964947?lang=en_us&edition=fundamental","pubTime":"2025-12-18 09:09","pubTimestamp":1766020158,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Inc. Releases Clinical Data on Anthracycline-Free Treatment for Early-Stage Triple Negative Breast Cancer. Intensity Therapeutics Inc. published a document regarding a new drug, INT230-6, in clinical testing for breast cancer treatment. The document describes ongoing research on INT230-6, which involves intratumoral injections to locally kill cancer cells and stimulate an immune response. The research focuses on its use in early-stage, operable triple negative breast cancer and explores the potential for anthracycline-free treatment regimens. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL2wndbm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2590988515","title":"Intensity Therapeutics Reports Favorable Early Results from Phase 2 Triple Negative Breast Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590988515","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590988515?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:47","pubTimestamp":1765457238,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Inc. has announced the presentation of two posters at the 2025 San Antonio Breast Cancer Symposium . The first poster, PS5-08-16, reports early observations from the INVINCIBLE-4 study, an ongoing randomized Phase 2 clinical trial investigating INT230-6 in combination with standard of care  neoadjuvant immunochemotherapy in patients with early-stage triple negative breast cancer . Preliminary data indicate that the INT230-6 cohort experienced 50% fewer grade 3 or higher adverse events compared to the SOC-alone cohort. Fourteen patients have been treated to date, with safety data for those receiving INT230-6 plus SOC remaining favorable. These results are being presented at the symposium. A second poster, PS4-10-15, outlines a potential Phase 3 clinical study design evaluating INT230-6 plus SOC, with and without the anthracycline doxorubicin, for breast cancer treatment. This presentation also takes place at the SABCS.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL27R3GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2589781231","title":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies","url":"https://stock-news.laohu8.com/highlight/detail?id=2589781231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589781231?lang=en_us&edition=fundamental","pubTime":"2025-12-06 03:14","pubTimestamp":1764962096,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companiesEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslette","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PKG","HL","HUM","FCX","TARA","EXE","LU0128525689.USD","BMEA","TTAN","AUB","TE","WBD","PSN","XOM","DBRG","EUDA","VSCO","PRAX","RBRK","LU0320765646.SGD","LU1150488218.USD","IOT","OMC","ULTA","TRMB","FSLY","CHPT","LU0128525929.USD","LUV","FANG","INTS","EQT","HPE","ITT","ROL","CDE","DELL","ALB","AES","S","AMLX","SCCO","ZUMZ","COO"],"gpt_icon":1},{"id":"2589180868","title":"BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's Secret","url":"https://stock-news.laohu8.com/highlight/detail?id=2589180868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589180868?lang=en_us&edition=fundamental","pubTime":"2025-12-05 22:22","pubTimestamp":1764944543,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Ulta Beauty, Victoria's SecretEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning Ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL6N3XB0LA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COO","CHPT","WBD","BMEA","SGXZ23171101.USD","LU1048596156.SGD","IOT","LU2477742899.HKD","LUV","LU0821914370.USD","LU2039709279.SGD","LU1863844665.USD","LU1035775433.USD","RBRK","INTS","QCLS","LU0719512351.SGD","TTAN","89888","ULTA","TRMB","RGEN","BK4170","ROL","BK4614","LU1232071149.USD","SW","LU0300736062.USD","TARA","IE00B0JY6N72.USD","LU0368265764.SGD","BK4123","PKG","LU0942090050.USD","LU1280957306.USD","LU1989764664.SGD","HPE","LU2401740654.USD","S","VSCO","PSN","ZUMZ","SWR.UK"],"gpt_icon":1},{"id":"2589892931","title":"BUZZ-Intensity Therapeutics jumps after Nasdaq grants compliance extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2589892931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589892931?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:40","pubTimestamp":1764938406,"startTime":"0","endTime":"0","summary":"BUZZ-Intensity Therapeutics jumps after Nasdaq grants compliance extension** Shares of drugmaker Intensity Therapeutics INTS.O rise 8.6% to 50 cents premarket ** Co gets 180-day extension from the Nasdaq exchange to meet the minimum $1 share price requirement** Deadline set for June 1, 2026; shares must stay above $1 for 10 consecutive days, says co** Co continues late-stage trials of INT230-6 for soft tissue sarcoma and breast cancer** INT230-6 is injected into tumors to kill cancer cells and trigger immune response - INTS** Up to last close, stock down ~74% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL4N3XB0YI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2589189257","title":"BRIEF-Intensity Therapeutics Granted 180-Day Extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2589189257","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589189257?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:39","pubTimestamp":1764938396,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Granted 180-Day Extension Dec 5 (Reuters) - Intensity Therapeutics Inc INTS.O:INTENSITY THERAPEUTICS GRANTED 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH NASDAQ'S MINIMUM B","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XA1AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2589892389","title":"Intensity Therapeutics Granted 180-Day Extension to Regain Compliance With Nasdaq's Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2589892389","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589892389?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:30","pubTimestamp":1764937817,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nFWN3XA1AN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2588870978","title":"BRIEF-Intensity Therapeutics Files For Offering Of Up To $30 Million Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588870978","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588870978?lang=en_us&edition=fundamental","pubTime":"2025-12-04 22:09","pubTimestamp":1764857355,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Files For Offering Of Up To $30 Million Common Stock - SEC FilingDec 4 (Reuters) - INTENSITY THERAPEUTICS INC - FILES FOR OFFERING OF UP TO $30 MILLION COMMON STOCK - SEC FILINGSource text: [ID:n0001567264-25-000108] ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2588881015","title":"Intensity Therapeutics Unveils New Breast Cancer Therapy Data at 2025 SABCS","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881015","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881015?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:47","pubTimestamp":1764852433,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Inc. announced two upcoming presentations at the 2025 San Antonio Breast Cancer Symposium, scheduled for December 9-12, 2025. The company will present new clinical research, including a study titled \"Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations,\" to be presented by Lewis Bender, M.S. M.A. M.B.A., on December 11, 2025. Another presentation, \"Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 , a Phase II Randomized Clinical Trial,\" will be presented by Andreas Müller, M.D., on December 12, 2025. The results of these studies will be presented at the symposium.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL21kT80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2588881024","title":"Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2588881024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588881024?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:47","pubTimestamp":1764852420,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA5P6J6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2588088996","title":"Intensity Therapeutics Inc - Files for Offering of up to $30 Mln Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588088996?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:03","pubTimestamp":1764849783,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0N5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INTS","BK4139"],"gpt_icon":0},{"id":"2583305380","title":"Analysts Offer Insights on Healthcare Companies: Curis (CRIS) and Intensity Therapeutics, Inc. (INTS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583305380","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583305380?lang=en_us&edition=fundamental","pubTime":"2025-11-13 00:00","pubTimestamp":1762963250,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Curis (CRIS – Research Report) and Intensity Therape...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-curis-cris-and-intensity-therapeutics-inc-ints-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-curis-cris-and-intensity-therapeutics-inc-ints-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU0029874061.USD","BK4139","XBI","INTS","LABU","BK4137","CRIS","BK4588","LU0128526141.USD","XLV","BK4581","HCSG"],"gpt_icon":0},{"id":"2581434420","title":"Intensity Therapeutics Q3 net loss narrows to $2.7 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581434420","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581434420?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:36","pubTimestamp":1762465011,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics Q3 net loss narrows to $2.7 mlnOverviewIntensity Therapeutics Q3 net loss narrows to $2.7 mln from $3.5 mln last yearCompany raised $13.6 mln since Q3 start, extending cash runw","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7026f4aef5369e29e112f6f82189519d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INTS","BK4139"],"gpt_icon":1},{"id":"2581501733","title":"Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2581501733","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581501733?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:03","pubTimestamp":1762463035,"startTime":"0","endTime":"0","summary":"Intensity Therapeutics reports $7.1 million cash as of September 30, 2025 and extends cash runway to end of first quarter 2027. Intensity Therapeutics Inc. reported cash and cash equivalents of $7.1 million as of September 30, 2025, with an additional $6.1 million raised in the fourth quarter of 2025, extending the company's cash runway until the end of the first quarter of 2027. Research and development expenses for the third quarter of 2025 were $1.6 million, down from $2.2 million in the same period of 2024, mainly due to reduced clinical trial costs following a pause in the INVINCIBLE-3 Study. The company plans to reinitiate patient enrollment in the INVINCIBLE-4 Study in the first quarter of 2026 after a protocol amendment. No sales or revenue figures were disclosed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7026f4aef5369e29e112f6f82189519d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL3VdtJV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":1},{"id":"2581012055","title":"BRIEF-Intensity Therapeutics Q3 Operating Income USD -2.733 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012055","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012055?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:02","pubTimestamp":1762462965,"startTime":"0","endTime":"0","summary":"BRIEF-Intensity Therapeutics Q3 Operating Income USD -2.733 Million\n\n\nNov 06 (Reuters) - Intensity Therapeutics Q3 basic EPS USD -0.06.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7026f4aef5369e29e112f6f82189519d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXCB026D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INTS"],"gpt_icon":0},{"id":"2581124740","title":"Intensity Therapeutics Q3 Basic EPS USD -0.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2581124740","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581124740?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:02","pubTimestamp":1762462920,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"7026f4aef5369e29e112f6f82189519d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXCB026D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INTS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intensitytherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0173},{"period":"1month","weight":-0.0276},{"period":"3month","weight":0.565},{"period":"6month","weight":0.2563},{"period":"1year","weight":-0.8526},{"period":"ytd","weight":-0.0046}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.","exchange":"NASDAQ","name":"Intensity Therapeutics, Inc.","nameEN":"Intensity Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intensity Therapeutics, Inc.(INTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Intensity Therapeutics, Inc.(INTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Intensity Therapeutics, Inc.,INTS,Intensity Therapeutics, Inc.股票,Intensity Therapeutics, Inc.股票老虎,Intensity Therapeutics, Inc.股票老虎国际,Intensity Therapeutics, Inc.行情,Intensity Therapeutics, Inc.股票行情,Intensity Therapeutics, Inc.股价,Intensity Therapeutics, Inc.股市,Intensity Therapeutics, Inc.股票价格,Intensity Therapeutics, Inc.股票交易,Intensity Therapeutics, Inc.股票购买,Intensity Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intensity Therapeutics, Inc.(INTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Intensity Therapeutics, Inc.(INTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}